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Ancuta Augustina Gheorghisan-Galateanu1,2Abstract
Background: Leydig cell tumors are the most common non-germ cell gonadal tumors with apparent increased
incidence in the last few years. They are usually benign tumors. We report a case of Leydig cell tumor of testis in a
patient presenting atypical features.
Case presentation: A 29-year-old Caucasian man, born with right cryptorchidism, corrected without medical
treatment before the age of two years, was diagnosed with Leydig cell tumor. Two years after diagnosis was
identified moderately elevated estradiol serum level, in the context of a significant overweight, hormonal changes
which had maintained after unilateral orchiectomy and after the patient's return to normal weight. Four years after
unilateral orchiectomy, elevated value of estradiol persisted and subdiaphragmatic micro lymphadenopathy was
observed.
Conclusions: Despite the favorable evolution of the patient four years after unilateral orchiectomy, long-term
follow-up is necessary to exclude recurrence or metastasis to the testis. The endocrine profile and imaging
investigations need to be repeated periodically. The changes in the hormonal assay and any new aspects on
computed tomography scan can be used as a marker of tumor recurrence and require careful screening and the
correct therapeutic decisions.
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Approximately 5-6% of all testis tumors are non-germ
cell tumors. Included in this group are sex cord/gonadal
stromal tumors, most originating from Leydig or Sertoli
cells, mixed tumors, and tumors of mesenchymal or
hematopoietic origin [1].
Leydig cell tumors (LCTs) are uncommon neoplasms
arising from gonadal stroma, accounting for 1-3% of all
testicular tumors in adults and 4% in prepubertal chil-
dren [2,3]. In the last few years the incidence of LCTs
seemed to increase well above the literature predictions
(14.7% of all testicular tumors removed). One possible
explanation for this phenomenon is the increasing use of
better ultrasound technology and the subsequent in-
creased detection of small nodules that have not been
found in historical series [4]. We communicate a case of
Leydig cell tumor with atypical evolution marked byCorrespondence: agheorghisan.a@gmail.com
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article, unless otherwise stated.maintaining of moderately elevated estradiol serum level
four years after unilateral orchiectomy.Case presentation
A 29-year-old Caucasian man presented to the endocrin-
ology department with a recent right testicular mass ob-
served at self-examination. The patient was born with
right cryptorchidism. The right testis moved down into
the scrotum before the age of two years old, without
medical treatment. His family history revealed a lung
cancer at his paternal grandfather. On physical examin-
ation the right testis was 6.5 × 3.5 cm in size, with a
palpable tumoral mass of approximately 1.93 × 1.30 cm
in size. No other sign, including gynecomastia or swell-
ing of superficial lymph nodes was observed. Scrotal
ultrasonography revealed a non-homogenous hypoecho-
genic tumoral mass in the right testis (Figure 1). Tumor
markers such as alpha-fetoprotein (AFP) and β-human
chorionic gonadotropin (β-hCG) were negative, and hor-
monal investigations were normal (Table 1). Surgery was
indicated but the patient refused. He returned to the
endocrinology department after two years with scrotal
pain in the last month. One year before the patient hased Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Ultrasound of a right testis with Leydig cell tumor. The tumor appears as a hypoechoic non-homogeneous mass within the
testicular parenchyma.
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tient overgrowth 30 kilos (at initial examination weight 90
kilos/height 195 cm). On physical examination the testicu-
lar tumor mass has not changed in size and scrotal ultra-
sonography had the same aspect, but gynecomastia was
present. The tumor markers (AFP and β-hCG) were also
negative and hormonal investigations were normal, except
moderately elevated estradiol level (E2) and low normal
level of testosterone (T) (Table 1). This time the patient ac-
cepted surgery. With a diagnosis of right testicular tumor,
radical right high orchiectomy was performed and the spe-
cimen has been submitted for histopathological examin-
ation. The final diagnosis of benign Leydig cell tumor of
testis was given (Figure 2). Immunohistochemical profileTable 1 Tumor markers and hormonal evaluation at baseline,
2 y Before After 1 y
Eralier Surgery Surgery After surg
AFP, ng/ml 2.26 1.80 2.88 2.16
β-hCG, mIU/ml 0.10 0.06 0.09 0.08
Total testosterone, ng/ml 4.23 1.80 2.40 4.60
Estradiol, pg/ml 26.31 80.22 61.31 78.4
LH, mIU/ml 5.34 1.76 2.40 4.58
FSH, mIU/ml 4.23 3.80 2.49 2.80
17-KS, mg/24 hours 23.4 17.9 18.75 18.8
17-HOCS, mg/24 hours 8.4 10.22 9.07 8.8
Progesterone, ng/ml - - 0.09 -
TSH, μUI/ml - 3.14 2.9 2.5
Abbreviations: AFP alpha-fetoprotein, β-hCG β-human chorionic gonadotropin, FSH f
17-ketosteroids, 17-HOCS urinary 17-hydroxycorticosteroid, TSH Thyroid-stimulatingshowed diffuse positive staining for Calretinin, Vimentin
and CD99 and negative staining for Synaptophysin and
Cytokeratin AE1/AE3. Hormonal investigations made after
surgery showed still the persistence of a moderate increase
of serum level of E2, while tumor markers AFP and β-hCG
were still negative (Table 1). The postsurgical evolution was
favorable. With diet and physical activity, the patient
returned to normal weight one year after the unilateral or-
chiectomy. Without further treatment, the patient was eval-
uated yearly. The blood tests including tumor markers and
hormonal investigations, along with scrotal ultrasound,
abdominal and pelvis computed tomography (CT) scan
were normal, except E2 serum level which was moderately
increased each time (Table 1). The abdominal CT scanafter surgery, and in the follow-up
2 y 3 y 4 y Normal
range
for age
ery After surgery After surgery After surgery
3.46 2.68 3.20 < 44
0.20 0.16 0.13 0.5-2.67
6.26 6.60 4.40 1.75-7.81
62.43 75.56 78.96 < 47
5.32 3.67 4.84 1.24-8.62
4.12 2.74 3.85 1.27-19.26
22.3 19.6 21.4 17-25
7.40 9.22 8.94 2-10
- - - 0.10-0.84
- - - 0.5-4.5
ollicle-stimulating hormone, LH luteinizing hormone, 17-KS urinary
hormone.
Figure 2 Leydig cell tumors of the testis. a. The tumor was surrounded by an incomplete, dense lamellar area. In non-neoplastic testicular
tissue, the seminiferous tubules showed Sertoli cells with complete spermatogenesis, hematoxylin-eosin stain x10 b. No evidence of necrosis, or
vascular invasion was seen. Stroma was fibrous with prominent vascularity, hematoxylin-eosin stain x10 c. The testicular tumor was composed of
nests, insular or pseudotubular pattern, hematoxylin-eosin and methylene blue stain x40 d. The tumor cells were large, polygonal, with acidophilic
to vacuolated cytoplasm and regular round nuclei, some with visible nucleoli. Mitoses were scarce, hematoxylin-eosin stain x40.
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matic micro lymphadenopathy (5–10 mm).Discussion
The etiology of LCTs is unknown and it seems to be het-
erogeneous. Furthermore, the molecular basis of LCTs is
poorly understood. Some studies showed a possible role
of genetic factors in the etiology of this tumor. Interest-
ingly, genetic mutations identified to date in child and
adult were different, and in some cases have been associ-
ated with other cancers [5].
Some authors have reported in Leydig tumors in adult
a somatic activating mutation in the guanine nucleotide-
binding protein α gene, which may result in tumor
development, leading to overexpression on the inhibin
alpha subunit and hyperactivity of the testosterone
biosynthetic pathway [6]. Also, in adult, it has been
reported inherited fumarate hydratase mutation which
appear to cause tumor growth through activation of the
hypoxia pathway [7]. Alterations in local stimuli, includ-
ing müllerian-duct inhibitory factor, inhibin, growth
factors, and temperature, may also create favorable
conditions for tumorigenesis [8].
LCTs are usually unilateral. However, 3-10% of them
have been estimated to be bilateral and 15% may extend
beyond the testis at the time of presentation. Origin
from testicular Leydig cells is demonstrable in most
cases, but rarely they may originate from the epididymis[9]. Although these tumors arise at any age, they affects
mostly men between 20–60 years old.
In our case the tumor was unilateral in right testis and
the patient belongs to the age group with the highest
incidence.
LCTs may be an incidental finding of a testicular mass
on scrotal ultrasonography performed for other condi-
tions [10]. Except for the testicular tumor mass present
in all cases, other signs and symptoms may be present in
different degrees (pain in the testis, enlargement of a tes-
ticle, heaviness in the scrotum, and gynecomastia).
Azoospermia and infertility are uncommon and, if exist
they are reversible after removal of the tumor [11].
Ultrasound of scrotum is very useful to confirm the
diagnosis of testicular tumor [12], but it cannot differentiate
between a benign and a malignant tumor [13]. In our case
scrotal ultrasonography has revealed a non-homogenous
hypoechogenic tumoral mass in the right testis.
In patients with LCTs the blood tests for tumor markers
(AFP, β- hCG, and lactate dehydrogenase) are negative.
The most common hormones secreted by LCTs are
testosterone and estrogens. In most cases, adults have
non functional testicular masses.
In our case tumor markers were always negative. Hor-
monal profile was initially normal. Two years after the
discovery of the tumor the occurrence of gynecomastia
and moderately elevated E2 serum level associated with
decreased T to lower normal serum value was observed.
After unilateral orchiectomy the blood tests were normal,
Table 2 Immunohistochemical staining results of Leydig
cell tumors
Marker Immunoreactivity
Benign Leydig cell tumors Inhibin A +
Calretinin* +














Malignant Leydig cell tumors Ki67 +
p53 +
Bcl2 +
Abbreviations: RLF/INSL3 Relaxin-like factor/Insulin-like 3, StAR-protein
Steroidogenic Acute Regulatory protein, SF-1 Steroidogenic factor 1, PLAP
Placental Alkaline Phosphatase. *Immunohistochemical tests performed in
our case.
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each time (Table 1).
The use of fine needle aspiration for diagnosis may be
an alternative to more invasive biopsy procedures in the
preoperative diagnosis of this rare testicular tumor [14].
CT scan of the abdomen and pelvis and chest radio-
graphy are indicated especially if malignancy is sus-
pected. In our case, except the tumor in the right testis,
CT scan was normal.
Orchiectomy is the initial treatment for LCTs, with or
without removal of nearby lymph nodes (lymphadenec-
tomy). Today, some authors suggest a more conservative
therapy. Testis sparing surgery has proved to be a feas-
ible and safe choice and could be regarded as first-line
therapy in cases of benign, small tumors (under 25 mm),
and young men [15-19].
Although orchiectomy is curative in approximately 90%
of cases, the remaining patients can develop metastases
refractory to chemotherapy and radiations. Radical orchi-
ectomy remains in use if malignancy is suspected [20].
In our case, based on family and personal medical his-
tory, radical right high orchiectomy was performed.
The pathological exam and immunohistochemistry are
essential for the diagnosis and for the next steps in treat-
ment. In our case, no histopathological feature suggest-
ive of malignancy was seen and the final diagnosis of
benign Leydig cell tumor of testis was given. The results
of immunoreactive tests were consistent with the exist-
ing literature (Table 2) [21-28].
While benign, LCTs have malignant potential in about
10% of cases with metastatic forms, particular to the
lymph nodes, especially the retroperitoneal and inguinal
nodes (70%), liver (45%), lungs (40%), and bone (25%)
[29]. The metastatic type occurs exclusively in adults
and is more common in older patients with an average
age of more than 40 years. The risk of malignancy in the
undescended testis is 4 to 10 times higher than that in
the general population but the most common type of
testicular cancer occurring in undescended testes is
seminoma [30].
Palazzo et al. have suggested that the majority of LCTs
are diploid and the less common malignant tumors are
typically aneuploid, and that deoxyribonucleic acid flow
cytometric findings can be useful as a prognostic indica-
tor in these tumors [31].
In our case all clinical, hormonal, immunocytochem-
ical, and pathological findings have supported the diag-
nosis of benign LCT.
Initially, starting from negative tumor markers and
normal hormonal profile, tumoral mass seemed to be a
non functional Leydig cell tumor, the only detectable
element has been testicular tumor mass. After two years
the occurrence of gynecomastia and moderately elevated
E2 serum level associated with decreased testosterone tolower normal serum value was observed which led to a
new considerations of the case presented. Leydig cells can
synthesize both androgens and estrogen, and this cells con-
tain the aromatase enzyme necessary to convert irreversibly
testosterone to estradiol [32]. There have been reported
cases of Leydig cell tumor which demonstrated only an in-
crease of serum E2 and suppression of serum testosterone
as a consequence of increased aromatase activity in tu-
moral Leydig cells [33]. The direct inhibitory action of ele-
vated E2 on the enzymes involved in steroidogenesis and
the negative feedback action on luteinizing hormone secre-
tion of the E2 possibly caused the suppression of serum
testosterone [34]. Due to the significant increase in weight
of the patient, in our case hormonal changes were rather
considered a consequence of aromatization in adipose
tissue of testosterone to estradiol and gynecomastia as a
consequence of increased levels of estradiol and change of
estrogen/androgen ratio. This assumption was confirmed
by maintaining high levels of estradiol after unilateral or-
chiectomy, because it was demonstrated that after remov-
ing the tumor, in most cases, hormone levels return to
normal, which in the case presented did not. Therefore has
been indicated to the patient the weight loss in the hope
that he will return to normal levels of estradiol and
gynecomastia will disappear. Surprisingly, after the return
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increased in the absence of any identifiable factors that
could explain the maintenance of high levels of estradiol,
such as red meat abuse consumption [35].
Statistics show that LCTs are rarely malignant and
they correlate with increasing age of the patient, tumor
size (over 5 cm) and increased tumor mitotic index.
These data were missing in our case. In 2002 Maeda et
al. raported on an adult patient with a larger testicular
tumor in whom metastasis of Leydig cell tumor was
suggested by elevated serum estradiol 9 years after the
removal of the primary tumor [36].
We cannot yet draw a conclusion. For four years our
patient remained free of disease, with no evidence of
recurrence or metastasis, but persistent moderate high
levels of estradiol and the result of the last abdominal
CT scan (subdiaphragmatic micro lymphadenopathy) do
not definitely exclude this possibility. It is known that
changes in hormonal assay can be used as a marker of
tumor recurrence in patients followed. Furthermore, the
patient has a family history of cancer and at birth he had
cryptorchidism. These data require careful monitoring
and correct therapeutic decisions. Although estradiol
levels are not suggestive for a malignant lesion, imaging
investigations are of great interest, and need to be
repeated periodically. Moreover, endocrine evaluation is
useful for patients with a Leydig cell tumor in whom
endocrinological abnormality is demonstrated. Many
times was told that the next step in such cases is “wait
and see”, which for our patient seems to be the most
appropriate thing.
Conclusions
Leydig cell tumors are uncommon neoplasms arising from
gonadal stroma. It is critical for physicians to remember
and do not overlook the possibility of this rare tumor. The
self-examination of testicles appears to be a very import-
ant step for the diagnosis of testicular tumors.
In Leydig cell tumors orchiectomy is the elected thera-
peutic decision. In the absence of any sign of malignancy,
long-term follow-up is necessary to exclude recurrence or
metastasis. Because we cannot always identify the reasons
of persistent elevated E2 serum level after unilateral orchi-
ectomy for Leydig cell tumors, the endocrine profile and
imaging investigations need to be repeated periodically.
Consent
Written informed consent was obtained from the patient
for publication of this Case Report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Abbreviations
LCTs: Leydig cell tumors; AFP: alpha-fetoprotein; β-hCG: β-human chorionic
gonadotropin; E2: Estradiol; T: Testosterone; CT: Computed tomography.Competing interests
The author declares that he has no competing interests.
Authors’ contributions
AAGG: collection and assembly of data, microscopic imaging in final form for
publication, manuscript writing, conception and final design. The author has
read and approved this final manuscript.
Acknowledgements
The author would like to thank Dr. L. Pop for his contribution in providing
immunocytochemistry data and pathologic diagnosis.
Received: 13 June 2014 Accepted: 16 September 2014
Published: 18 September 2014
References
1. Dilworth JP, Farrow GM, Oesterling JE: Non-germ cell tumors of testis.
Urology 1991, 37:399–417.
2. Emerson RE, Ulbright TM: Morphological approach to tumours of the
testis and paratestis. J Clin Pathol 2007, 60:866–880.
3. Cheville JC: Classification and pathology of testicular germ cell and sex
cord-stromal tumors. Urol Clin North Am 1999, 26:595–609.
4. Leonhartsberger N, Ramoner R, Aigner F, Stoehr B, Pichler R, Zangerl F,
Fritzer A, Steiner H: Increased incidence of Leydig cell tumours of the
testis in the era of improved imaging techniques. BJU Int 2011,
108:1603–1607.
5. Giacaglia LR, Kohek MB da F, Carvalho FM, Fragoso MC, Mendonca B,
Latronico AC: No evidence of somatic activating mutations on
gonadotropin receptor genes in sex cord stromal tumors.
Fertil Steril 2000, 74:992–995.
6. Libe R, Fratticci A, Lahlou N, Jornayvaz FR, Tissier F, Louiset E,
Guibourdenche J, Vieillefond A, Zerbib M, Bertherat J: A rare cause of
hypertestosteronemia in a 68-year-old patient: a Leydig cell tumor due
to a somatic GNAS (guanine nucleotide-binding protein, alpha-stimulating
activity polypeptide 1)-activating mutation. J Androl 2012, 33:578–584.
7. Carvajal-Carmona LG, Alam NA, Pollard PJ, Jones AM, Barclay E, Wortham N,
Pignatelli M, Freeman A, Pomplun S, Ellis I, Poulsom R, El-Bahrawy MA,
Berney DM, Tomlinson IP: Adult leydig cell tumors of the testis caused by
germline fumarate hydratase mutations. J Clin Endocrinol Metab 2006,
91:3071–3075.
8. Lejeune H, Habert R, Saez JM: Origin, proliferation and differentiation of
Leydig cells. J Mol Endocrinol 1998, 20:1–25.
9. Huang Y, Song J, Xu M, Zan Q: Primary Leydig cell tumour of epididymis:
a rare case report with review of literature. Andrologia 2013, 45:430–433.
10. Butruille C, Marcelli F, Ghoneim T, Lemaitre L, Puech P, Leroy X, Rigot JM:
Management of testicular lesions in a population of infertile patients.
Prog Urol 2012, 22:45–52.
11. Markou A, Vale J, Vadgama B, Walker M, Franks S: Testicular leydig cell
tumor presenting as primary infertility. Hormones (Athens) 2002,
1:251–254.
12. Negri L, Benaglia R, Fiamengo B, Pizzocaro A, Albani E, Levi Setti PE: Cancer
risk in male factor-infertility. Placenta 2008, 29(Suppl B):178–183.
13. Amatya NZM, Sapkota PK: Leydig cell tumor: a case report. Nepal J Radiol
2012, 2:39–41.
14. Handa U, Sood T, Punia RS: Testicular Leydig cell tumor diagnosed on
fine needle aspiration. Diagn Cytopathol 2010, 38:682–684.
15. Henderson CG, Ahmed AA, Sesterhenn I, Belman AB, Rushton HG:
Enucleation for prepubertal leydig cell tumor. J Urol 2006, 176:703–705.
16. Loeser A, Vergho DC, Katzenberger T, Brix D, Kocot A, Spahn M, Gerharz EW,
Riedmiller H: Testis-sparing surgery versus radical orchiectomy in patients
with Leydig cell tumors. Urology 2009, 74:370–372.
17. Passman C, Urban D, Klemm K, Lockhart M, Kenney P, Kolettis P: Testicular
lesions other than germ cell tumours: feasibility of testis-sparing surgery.
BJU Int 2009, 103:488–491.
18. Guana R, Mussa A, Lala R, Tessaris D, Tessiatore PM, Canavese F: Surgical
enucleation of testicular leydigioma in a young child: case report and
literature review. J Pediatr Endocrinol Metab 2011, 24:839–842.
19. Garcia M, Dargallo T, Palacios M, Carames J, Gomez J, Sacristan F, Vela D:
Leydig cell tumour: enucleation as a therapeutic choice in a case with
atypical symptoms. Arch Esp Urol 2012, 65:897–899.
Gheorghisan-Galateanu BMC Research Notes 2014, 7:656 Page 6 of 6
http://www.biomedcentral.com/1756-0500/7/65620. Bertram KA, Bratloff B, Hodges GF, Davidson H: Treatment of malignant
Leydig cell tumor. Cancer 1991, 68:2324–2329.
21. Iczkowski KA, Bostwick DG, Roche PC, Cheville JC: Inhibin A is a sensitive
and specific marker for testicular sex cord-stromal tumors. Mod Pathol
1998, 11:774–779.
22. Busam KJ, Iversen K, Coplan KA, Old LJ, Stockert E, Chen YT, McGregor D,
Jungbluth A: Immunoreactivity for A103, an antibody to melan-A
(Mart-1), in adrenocortical and other steroid tumors. Am J Surg Pathol
1998, 22:57–63.
23. Bremmer F, Schweyer S, Martin-Ortega M, Hemmerlein B, Strauss A,
Radzun HJ, Behnes CL: Switch of cadherin expression as a diagnostic tool
for Leydig cell tumours. APMIS 2013, 121:976–981.
24. McCluggage WG, Shanks JH, Whiteside C, Maxwell P, Banerjee SS, Biggart
JD: Immunohistochemical study of testicular sex cord-stromal tumors,
including staining with anti-inhibin antibody. Am J Surg Pathol 1998,
22:615–619.
25. Hekimgil M, Altay B, Yakut BD, Soydan S, Ozyurt C, Killi R: Leydig cell tumor
of the testis: comparison of histopathological and immunohistochemical
features of three azoospermic cases and one malignant case. Pathol Int
2001, 51:792–796.
26. Iczkowski KA, Butler SL: New immunohistochemical markers in testicular
tumors. Anal Quant Cytol Histol 2006, 28:181–187.
27. Dong L, Wang H, Su Z, Niu S, Wang R, Wu L, Chen G: Steroidogenic acute
regulatory protein is a useful marker for Leydig cells and sex-cord
stromal tumors. Appl Immunohistochem Mol Morphol 2011, 19:226–232.
28. Sangoi AR, McKenney JK, Brooks JD, Higgins JP: Evaluation of SF-1
expression in testicular germ cell tumors: a tissue microarray study of
127 cases. Appl Immunohistochem Mol Morphol 2013, 21:318–321.
29. Farkas LM, Szekely JG, Pusztai C, Baki M: High frequency of metastatic
leydig cell testicular tumors. Oncology 2000, 59:118–121.
30. Trabert B, Zugna D, Richiardi L, McGlynn KA, Akre O: Congenital
malformations and testicular germ cell tumors. Int J Cancer 2013,
133:1900–1904.
31. Palazzo JP, Petersen RO, Young RH, Scully RE: Deoxyribonucleic acid flow
cytometry of testicular Leydig cell tumors. J Urol 1994, 152:415–417.
32. Carreau S, Bois C, Zanatta L, Silva FR, Bouraima-Lelong H, Delalande C:
Estrogen signaling in testicular cells. Life Sci 2011, 89:584–587.
33. Masumori N, Kumamoto Y, Itoh N, Tsukamoto T, Miyao N, Koroku M,
Hirose T, Takahashi S: Leydig cell tumor: a case report with reference to
its endocrinological features. Eur Urol 1993, 24:302–304.
34. Rieu M, Kuhn JM, Mandard JC, Bottet P, Lemonnier D, Bekka S, Mahoudeau J:
Luteinizing hormone regulation by sex steroids in men with germinal
and Leydig cell tumours. Clin Endocrinol (Oxf ) 1993, 38:487–493.
35. Tavolini IM, Rossato M, Milani C, Dal Moro F: Estradiol plasma levels
elevation during follow-up for testicular Leydig-cell tumor is not an
unfailing sign of recurrence. Arch Ital Urol Androl 2007, 79:141–142.
36. Maeda T, Itoh N, Kobayashi K, Takahashi A, Masumori N, Tsukamato T:
Elevated serum estradiol suggesting recurrence of Leydig cell tumor
nine years after radical orchidectomy. Int J Urol 2002, 9:659–661.
doi:10.1186/1756-0500-7-656
Cite this article as: Gheorghisan-Galateanu: Leydig cell tumors of the
testis: a case report. BMC Research Notes 2014 7:656.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
